IRIS
ADAMO, Vincenzo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 14.092
NA - Nord America 12.224
AS - Asia 6.287
SA - Sud America 2.120
Continente sconosciuto - Info sul continente non disponibili 302
AF - Africa 180
OC - Oceania 13
Totale 35.218
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.961
RU - Federazione Russa 6.996
SG - Singapore 2.709
BR - Brasile 1.828
CN - Cina 1.810
IE - Irlanda 1.625
SE - Svezia 1.613
IT - Italia 816
HK - Hong Kong 681
DE - Germania 573
PL - Polonia 526
UA - Ucraina 505
FR - Francia 499
GB - Regno Unito 313
FI - Finlandia 294
VN - Vietnam 291
IN - India 194
CA - Canada 112
AR - Argentina 108
BD - Bangladesh 96
BE - Belgio 73
MX - Messico 69
IQ - Iraq 63
AT - Austria 61
ZA - Sudafrica 60
JP - Giappone 58
TR - Turchia 53
CO - Colombia 49
ID - Indonesia 45
EC - Ecuador 41
ES - Italia 41
UZ - Uzbekistan 35
VE - Venezuela 33
MA - Marocco 31
NL - Olanda 31
PK - Pakistan 31
PH - Filippine 23
AE - Emirati Arabi Uniti 19
KE - Kenya 19
JM - Giamaica 18
SA - Arabia Saudita 18
TN - Tunisia 18
NP - Nepal 17
AL - Albania 16
CZ - Repubblica Ceca 16
PY - Paraguay 16
CL - Cile 14
CR - Costa Rica 14
AZ - Azerbaigian 13
DO - Repubblica Dominicana 13
IL - Israele 13
JO - Giordania 13
MY - Malesia 13
DZ - Algeria 12
EG - Egitto 12
KG - Kirghizistan 12
LT - Lituania 12
PE - Perù 11
KZ - Kazakistan 10
OM - Oman 10
BO - Bolivia 9
HN - Honduras 9
IR - Iran 9
CH - Svizzera 8
EU - Europa 8
PS - Palestinian Territory 8
UY - Uruguay 8
AU - Australia 7
BG - Bulgaria 7
HR - Croazia 7
LB - Libano 7
LV - Lettonia 7
NI - Nicaragua 7
RO - Romania 7
SK - Slovacchia (Repubblica Slovacca) 7
TH - Thailandia 7
CI - Costa d'Avorio 6
RS - Serbia 6
AO - Angola 5
GE - Georgia 5
HU - Ungheria 5
NZ - Nuova Zelanda 5
PA - Panama 5
XK - ???statistics.table.value.countryCode.XK??? 5
BA - Bosnia-Erzegovina 4
DK - Danimarca 4
ET - Etiopia 4
GT - Guatemala 4
NO - Norvegia 4
TT - Trinidad e Tobago 4
AM - Armenia 3
BN - Brunei Darussalam 3
GA - Gabon 3
GR - Grecia 3
LU - Lussemburgo 3
MN - Mongolia 3
SN - Senegal 3
SY - Repubblica araba siriana 3
A2 - ???statistics.table.value.countryCode.A2??? 2
EE - Estonia 2
Totale 34.892
Salva come PNG Salva come JPEG
Città #
Moscow 2.045
Dublin 1.619
Ashburn 1.585
Singapore 1.508
Chandler 1.366
Dallas 1.078
Jacksonville 1.013
Nyköping 847
Hong Kong 679
Beijing 639
San Jose 576
Warsaw 508
Council Bluffs 381
New York 350
The Dalles 326
Ann Arbor 276
Princeton 272
Los Angeles 266
Medford 258
Dearborn 250
Cambridge 239
Lauterbourg 229
Des Moines 213
Messina 172
Boardman 167
São Paulo 149
Buffalo 137
Tianjin 96
Munich 93
Woodbridge 85
Jinan 83
Frankfurt am Main 79
Santa Clara 76
Ho Chi Minh City 75
Brussels 71
Lancaster 71
Hanoi 70
Pune 61
Wilmington 60
Rio de Janeiro 57
Orem 56
Shenyang 55
Redondo Beach 54
San Mateo 54
Belo Horizonte 52
Brooklyn 49
Tokyo 49
Guangzhou 48
Vienna 47
Dong Ket 46
Nanjing 42
Chennai 41
Houston 40
Johannesburg 36
Montreal 35
Chicago 34
Hebei 34
San Francisco 34
Columbus 33
London 33
Phoenix 33
Zhengzhou 33
Brasília 32
Tashkent 32
Turku 30
Nuremberg 29
Atlanta 28
Seattle 28
Milan 27
Porto Alegre 27
Shanghai 27
Shenzhen 27
Stockholm 27
Helsinki 26
Haikou 25
Jakarta 25
Manchester 24
Boston 23
Campinas 23
Hangzhou 23
Baghdad 22
Mumbai 22
Rome 22
Denver 21
Mexico City 21
Nanchang 21
Changsha 20
Goiânia 20
Leawood 19
Ningbo 19
Quito 19
Taizhou 19
Toronto 19
Curitiba 18
Jiaxing 18
Nairobi 18
Amsterdam 17
Düsseldorf 17
Guarulhos 17
Washington 17
Totale 19.932
Salva come PNG Salva come JPEG
Nome #
PARAGANGLIOMA MALIGNO DEL CORPO CAROTIDEO.Rilievi Clinici, Morfologici, Istochimici E Ultrastrutturali Su Un Caso. 429
A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): old successes and future perspectives 246
Validation of the OAKS prognostic model for acute kidney injury after gastrointestinal surgery 244
CyberKnife Radiosurgery Alone or Combined with "Dose Dense" Temozolomide Administration for Recurrent Gliomas. 242
Breast safety and efficacy of genistein aglycone for postmenopausal bone loss: a follow-up study 241
Prognostic value of methlylenetetrahydrofolate reductase (MTHFR), thymidylate synthase (TS) promoter, and p53 codon 72 variants and survival in advanced non-small cell lung cancer (NSCLC). 239
zd1839"iressa" in heavily pretreated patients with advaned/metastatic non-small cell lung cancer(NSCLC):assessment of tolerability and the clinical benefit 227
Activity of pegylated liposomal doxorubicin in combination with gemcitabine in triple negative breast cancer with skin involvement: Two case reports. 221
Androgen Receptor (AR), E-Cadherin, and Ki-67 as emerging targets and novel prognostic markers in triple-negative breast cancer (TNBC) patients 218
Correction to: Changes in surgicaL behaviOrs dUring the CoviD-19 pandemic. The SICE CLOUD19 Study 218
Su di un caso di pseudomyxoma peritonei con diffusione spontanea alla pleura. 216
Androgen receptor (AR), E-cadherin, and Ki-67 as prognostic markers in triple-negative breast cancer (TNBC). 212
Baseline neutrophilia, derived neutrophil-to-lymphocyte ratio (dNLR), platelet-to-lymphocyte ratio (PLR), and outcome in non small cell lung cancer (NSCLC) treated with Nivolumab or Docetaxel 207
Epirubucin (EPI) and Paclitaxel (TAX) in advanced breast cancer.a phase II studyi 206
An immunohistochemical investigation of pre-metastatic niche (PMN) in node-negative invasive breast carcinomas 206
The prognostic significance of combined androgen receptor, E-Cadherin, Ki67 and CK5/6 expression in patients with triple negative breast cancer 202
Impact of integrated treatments on patient management in solid tumors: from diagnosis to palliative care. 198
Activity and safety of gefitinib and erlotinib in metastatic non-small cell lung cancer (NSCLC): A comparative analysis. 198
Interleukin-22 serum concentration in colon-rectal cancer patients and clinical correlations: our experience. 195
A study of endometrial adenocarcinoma treated with tamoxifen by scanning and transmission electron microscopy. 193
[Serum levels of copper and zinc in patients with lung cancer] 192
Folate pathway implications in advanced Non Small Cell Lung Cancer (NSCLC): impact of thymidylate synthase (TS) promoter and methlylenetetrahydrofolate reductase (MTHFR) C677T and A1298C variants expression on patients’ outcome and correlation with p53 codon 72 mutations. 192
Immunoexpression of lactoferrin in triple-negative breast cancer patients: A proposal to select a less aggressive subgroup 190
A PHASE II STUDY (21 DAY REGIMEN) OF GEMCITABINE AND CISPLATIN IN TRANSITIONAL CELL CARCINOMA OF BLADDER 188
ACTIVITY AND TOXICITY OF GEMCITABINE AND GEMCITABINE + VINORELBINE IN ADVANCED NSCLC EDERLY PATIENTS .PHASE II DATA FROM THE MULTICENTER ITALIAN LUNG CANCER IN THE ELDERLY STUDY(MILES) RANDOMIZED TRIAL 186
Gemcitabine (GEM) and cisplatin (CIS) in advanced/metastatic transitional cell carcinoma (TCC) of bladder:phase II study 186
Heterogeneous responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with uncommon EGFR mutations: New insights and future perspectives in this complex clinical scenario 186
Bone health assessment by quantitative ultrasound and dual-energy x-ray absorptiometry in postmenopausal women with breast cancer receiving aromatase inhibitors 185
Phase II study of gemcitabine and cisplatin in patients with advanced or metastatic bladder cancer: long-term follow-up of a 3-week regimen 184
Evaluation of quality of life of patients submitted to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinosis of gastrointestinal and ovarian origin and identification of factors influencing outcome. 184
A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: A real-world experience 184
Preliminary study of pre-metastatic niche (PMN) in nonmetastatic nodes for the assessment of metastasis risk in breast cancer (BC). 183
Emerging role of Radium-223 in the growing therapeutic armamentarium of metastatic castration-resistant prostate cancer 182
Changes in surgicaL behaviOrs dUring the CoviD-19 pandemic. The SICE CLOUD19 Study 182
Intralesional sonographically guided injections of lymphokine- activated killer cells and recombinant interleukin-2 for the treatment of liver tumors: A pilot study 182
Circulating miR-22, miR-24 and miR-34a as novel predictive biomarkers to pemetrexed-based chemotherapy in advanced non small cell lung cancer. 178
HER-2 overexpression in advanced node-positive gastric carcinomas: is there any relationship with other clinico-pathological histoprognostic parameters? 178
A new method for titration of oral transmucosal fentanyl citrate (OTFC) starting dose in cancer patients. 177
Interleukin-22 serum concentration in colon-rectal cancer patients and clinical correlations: our experience. 177
Central nervous system involvement in ALK-rearranged NSCLC: promising strategies to overcome crizotinib resistance 176
gemcitabine and pegylated liposomial doxorubicin in recurrent epithelial ovarian cancer (REOC).Preliminary report a phase II study 175
Clinical significance of circulating interleukin-23 as a prognostic factor in breast cancer patients. 174
Can we better manage advanced NSCLC in the elderly with the new therapeutic agents? Preliminary analysis of a real life multicenter study. 174
Brain metastases in patients with non-small cell lung cancer: focus on the role of chemotherapy. 173
Gefitinib versus Erlotinib treatment in Non Small Cell Lung Cancer (NSCLC): comparison of two clinical experiences. 173
The treatment of peritoneal carcinomatosis in elderly patients. 173
Biological parameters in breast cancer. 173
Detection Of Lynphocytic β - Endorphin In Cancer Patients During Hospedalization And After In Vitro Culture With IL 2. 173
Bleomycin, epirubicin, carboplatin (BECA) in the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck 172
Breast. La terapia primaria: stato dell'arte 172
Activity and tolerability of cisplatin (CDDP) and fotemustine (FTM) in non-small cell lung cancer (NSCLC) patients (PTS) with brain metastases (BM): A multicentric phase II study of the Gruppo Oncologico dell'Italia Meridionale (GOIM). 172
A randomised factorial trial of sequential doxorubicin and CMF vs CMF and chemotherapy alone vs chemotherapy followed by goserelin plus tamoxifen as adjuvant treatment of node-positive breast cancer. 170
Hereditary breast/ovarian cancer families: The impact of mutation prediction models on BRCA1/2 mutation screening costs. 170
AIOM Conference 2004. Docetaxel: a recent conquest in the adjuvant therapy of breast cancer 169
A double-blind randomized study comparing intramuscular (i.m.) granisetron with i.m. granisetron plus dexamethasone in the prevention of delayed emesis induced by cisplatin 169
Antiblastic treatment of advanced cervical carcinoma and its recurrences: assessment of four different polychemotherapies used for a decade. 169
Intralesional sonographically guided injections of lymphokine-activated killer cells and recombinant interleukin-2 for the treatment of liver tumors: a pilot study. 168
Second-line therapy in advanced non-small cell lung cancer: Cytotoxic agents or tyrosine kinase inhibitors? Our experience. 168
Extended RAS mutation testing on wild-type KRAS exon 2 metastatic colorectal cancer. 168
FCM detection of lymphocytic beta-endorphin in cancer patients during hospitalization and after in vitro culture with IL2 167
Gemcitabine (GEM) and cisplatin (Cis) in advanced/metastatic transitional cell carcinoma (TCC) of bladder: Phase II study 167
SPONTANEOUS TRANSFORMATION AND IMMORTALIZATION OF PERITONEAL- MACROPHAGES OF HUMAN-ORIGIN 167
Maintenance Therapy with Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients with RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial 167
The palliative role of Gefitinib (Iressa) in the treatment of heavily pretreated patients with advanced, refractory non small cell lung cancer. Results of a 3-year experience. 166
Safety of Capecitabine plus Bevacizumab in heavily treated patients with metastatic colorectal cancer (MCRC) 166
Unusual relapse of hepatocellular carcinoma 166
Etoposide, l-leucovorin and fluorouracil (ELF) regimen in metastatic gastric cancer: a phase II study. J Chemother. 1999 Feb;11(1):74-7. PMID: 10078785 [PubMed - indexed for MEDLINE] 166
Epidermal growth factor receptor (EGFR) G719C mutation as new determinant of long term survival and response in patients with non small cell lung cancer treated with erlotinib: 165
Efficacy of T-DM1 for leptomeningeal and brain metastases in a HER2 positive metastatic breast cancer patient: New directions for systemic therapy - a case report and literature review 165
Il ruolo dell'ormonoterapia nel carcinoma della mammella in eta' geriatrica 164
Is the adenocarcinoma subtype a predictor of response to Pemetrexed in patients with non small cell lung cancer? Our preliminary data 164
Correction: Androgen Receptor (AR), E-cadherin, and Ki-67 as emerging targets and novel prognostic markers in Triple-Negative Breast Cancer (TNBC) patients 164
VP16, epirubicin and procarbazine in the treatment of advanced non-small-cell lung cancer. 163
Author Correction to: Prevalence of Use and Cost of Biological Drugs for Cancer Treatment: A 5-Year Picture from Southern Italy 163
Current knowledge and future directions on bisphosphonate-related osteonecrosis of the jaw in cancer patients 160
Is the adenocarcinoma subtype a predictor of response to Pemetrexed in patients with non small cell lung cancer? Our preliminary data. 160
Combination of Gemcitabine (GEM and Liposomal Pegylate Doxorubicin (PLD) in recurrent/ metastatic breast carcinoma: a phase II study. 159
ZD 1839 IRESSA IN HEAVILY PRETREATED PATIENTS WITH ADVANCED/METASTATIC NON SMALL CELL LUNG CANCER:ASSESSMENT OF TOLERABILITY AND CLINICAL BENEFIT 159
Etoposide, l-leucovorin and fluorouracil (ELF) regimen in metastatic gastric cancer: A phase II study 158
Induction chemotherapy with paclitaxel and cisplatin to concurrent radiotherapy and weekly paclitaxel in the treatment of loco-regionally advanced, stage IV (M0), head and neck squamous cell carcinoma. Mature results of a prospective study. 158
Correlation between serum magnesium levels and skin toxicity during cetuximab treatment in squamous cell carcinoma of head and neck cancer (SCCHN): the role of weekly intravenous magnesium supplementation. 158
Ipsilateral supraclavicular lymph nodes metastases from breast cancer as only site of disseminated disease. Chemotherapy alone vs. induction chemotherapy to radical radiation therapy 157
An observational time and motion study of denosumab subcutaneous injection and zoledronic acid intravenous infusion in patients with metastatic bone disease: results from three European countries 157
Nab-paclitaxel and trastuzumab combination: A promising approach for neoadjuvant treatment in HER2-positive breast cancer 157
A phase I/II trial of gefitinib and radiotherapy in patients with locally advanced inoperable squamous cell carcinoma of the head and neck. 156
Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial. 156
Influence of EGFR mutational status on metastatic behavior in non squamous non small cell lung cancer 156
Peritoneal carcinomatosis of colorectal origin. 155
Liquid biopsy tracking of lung tumor evolutions over time 155
TCC superficiale della vescica: identificazione nel sedimento urinario di mediatori di proliferazione cellulare quali possibili indici di recidiva e progressione neoplastica. 154
Gemcitabine and liposomal doxorubicin in the salvage treatment of ovarian cancer: Updated results and long-term survival. 153
Trattamento palliativo dei tumori del retto-sigma mediante elettrocoagulazione endoscopica.” 153
Impact of integrated treatments on patient management in solid tumors: From diagnosis to palliative care. 151
Third generation EGFR TKIs in EGFR-mutated NSCLC: Where are we now and where are we going 151
IL-33/IL-31 axis: A new pathological mechanism for epidermal growth factor receptor tyrosine kinase inhibitors-associated skin toxicity? 151
First Line Chemotherapy with Oral Vinorelbine (oV) in Elderly Hormone-Refractory Prostate Cancer (HRPC) Patients (pts 149
Predicting sensitivity of non small cell lung cancer to gefitinib and erlotinib: is there still a role for clinical factors ? 149
Impact of erlotinib on overall survival in non small cell lung cancer patients: is the post progression survival a new paradigm? 148
Role of Androgen Receptor (AR), Ki 67 and E-cadherin as prognostic markers in Triple Negative Breast Cancer (TNBC) 148
Treatment of advanced and/or metastatic epidermoid carcinoma of the head and neck: an effective combination chemotherapy with bleomycin, methotrexate and ftorafur. 147
Totale 17.980
Salva come PNG Salva come JPEG
Categoria #
all - tutte 114.093
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 114.093
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.753 0 244 30 45 58 16 106 63 15 320 265 591
2022/20235.013 389 493 216 417 379 512 80 325 1.984 19 141 58
2023/20241.301 101 186 69 108 71 498 66 56 5 46 11 84
2024/20255.070 66 47 92 313 258 168 106 1.119 1.341 292 416 852
2025/202615.360 751 924 1.075 857 1.249 3.559 1.978 2.029 1.902 556 219 261
2026/2027760 235 525 0 0 0 0 0 0 0 0 0 0
Totale 35.218